Anthracyclines are frequently used for the treatment of breast cancer and topoisomerase II
alpha (TOP2A) is considered to be the molecular target. Numerous studies have evaluated …

Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors
differ in their pathology. Analysis of larger datasets of mutation carriers should allow further …

To identify colorectal cancer (CRC) susceptibility alleles, we conducted a genome-wide
association study. In phase 1, we genotyped 550,163 tagSNPs in 940 familial colorectal tumor …

Germline BRCA1 mutations predispose to breast cancer. To identify genetic modifiers of this
risk, we performed a genome-wide association study in 1,193 individuals with BRCA1 …

PURPOSE To provide precise age-specific risk estimates of cancers other than female breast
and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for …

Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC)
susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and …

The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported
in single populations, with the majority of reports focused on White in Europe and North …

The American College of Medical Genetics and Genomics (ACMG)/Association for Molecular
Pathology (AMP) framework for classifying variants uses six evidence categories related to …

Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men.
Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We …

Purpose: It is not clear that the published estimates of the breast and ovarian cancer
penetrances of mutations in BRCA1 and BRCA2 can be used in genetic counseling in countries …